A Novel, Likely Pathogenic MAX Germline Variant in a Patient With Unilateral Pheochromocytoma
Open Access
- 3 June 2021
- journal article
- research article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (8), bvab085
- https://doi.org/10.1210/jendso/bvab085
Abstract
Context Inherited MYC-associated factor X (MAX) gene pathogenic variants (PVs) increase risk for pheochromocytomas (PCCs) and/or paragangliomas (PGLs) in adults and children. There is little clinical experience with such mutations. Objective This report highlights an important approach. Methods Clinical assessment, including blood chemistry, imaging studies, and genetic testing were performed. Results A 38-year-old Hispanic woman was diagnosed with PCC in 2015, treated with adrenalectomy, and referred to endocrinology clinic. Notably, she presented to her primary care physician 3 years earlier complaining of left flank pain, intermittent diaphoresis, and holocranial severe headache. We confirmed severe hypertension (180/100 mm Hg) over multiple antihypertensive regimens. Biochemical and radiological studies workup revealed high plasma metanephrine of 255 pg/mL (normal range, < 65 pg/mL) and plasma normetanephrine of 240 pg/mL (normal range, < 196 pg/mL). A noncontrast computed tomography scan of the abdomen revealed a 4.2 × 4.3 × 4.9-cm, round-shaped and heterogenous contrast enhancement of the left adrenal gland, and a 2-mm nonobstructive left kidney stone. A presumptive diagnosis of secondary hypertension was made. After pharmacological therapy, laparoscopic left adrenalectomy was performed and confirmed the diagnosis of pheochromocytoma. Based on her age, family history, and a high suspicion for genetic etiology, genetic testing was performed that revealed the presence of a novel likely pathogenic variant involving a splice consensus sequence in the MAX gene, designated c0.64-2A > G. Conclusion The phenotype of MAX PV-related disease and paraganglioma are highlighted. The novel c0.64-2A > G mutation is reported here and should be considered in the diagnostic workup of similar cases.Funding Information
- Breast Cancer Research Foundation (BCRF-19-172)
- Conquer Cancer Research Professorship in Breast Cancer Disparities
- National Cancer Institute
- National Institutes of Health (RC4CA153828)
This publication has 27 references indexed in Scilit:
- Pheo-Type: A Diagnostic Gene-expression Assay for the Classification of Pheochromocytoma and ParagangliomaJournal of Clinical Endocrinology & Metabolism, 2016
- Complex MAX Rearrangement in a Family With Malignant Pheochromocytoma, Renal Oncocytoma, and ErythrocytosisJournal of Clinical Endocrinology & Metabolism, 2016
- Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patientsJournal of Medical Genetics, 2015
- Genetics of pheochromocytoma and paraganglioma in Spanish pediatric patientsEndocrine-Related Cancer, 2013
- MAX and MYC: A Heritable BreakupCancer Research, 2012
- MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and ParagangliomaClinical Cancer Research, 2012
- An Update on the Genetics of Paraganglioma, Pheochromocytoma, and Associated Hereditary SyndromesHormone and Metabolic Research, 2012
- Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytomaNature Genetics, 2011
- Bilateral Adrenal Medullary Hyperplasia Associated With an SDHB MutationJournal of Clinical Oncology, 2011
- VON RECKLINGHAUSEN′S DISEASE AND PHEOCHROMOCYTOMASJournal of Urology, 1999